Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Lowered to $12.00 at Evercore ISI

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price objective decreased by Evercore ISI from $20.00 to $12.00 in a research report report published on Monday,Benzinga reports. Evercore ISI currently has an outperform rating on the biotechnology company’s stock.

Several other research firms have also recently weighed in on ENTA. JMP Securities boosted their price objective on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 12th. Westpark Capital initiated coverage on Enanta Pharmaceuticals in a report on Tuesday, September 2nd. They issued a “buy” rating and a $24.00 target price on the stock. HC Wainwright initiated coverage on Enanta Pharmaceuticals in a report on Monday, July 28th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Wall Street Zen raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, June 22nd. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, Enanta Pharmaceuticals has an average rating of “Buy” and an average target price of $20.20.

Enanta Pharmaceuticals Trading Down 9.9%

ENTA opened at $7.46 on Monday. The stock has a market cap of $159.49 million, a price-to-earnings ratio of -1.73 and a beta of 0.84. Enanta Pharmaceuticals has a 1 year low of $4.09 and a 1 year high of $13.37. The stock has a fifty day moving average price of $7.85 and a 200 day moving average price of $6.78.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%.The company had revenue of $18.31 million during the quarter, compared to analysts’ expectations of $16.21 million. As a group, sell-side analysts forecast that Enanta Pharmaceuticals will post -4.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ENTA. Millennium Management LLC lifted its position in Enanta Pharmaceuticals by 50.2% during the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after acquiring an additional 449,945 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Enanta Pharmaceuticals by 674.7% in the first quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock valued at $1,971,000 after buying an additional 311,010 shares in the last quarter. Stonepine Capital Management LLC raised its position in shares of Enanta Pharmaceuticals by 78.0% in the first quarter. Stonepine Capital Management LLC now owns 590,742 shares of the biotechnology company’s stock valued at $3,261,000 after buying an additional 258,842 shares in the last quarter. Trexquant Investment LP raised its position in shares of Enanta Pharmaceuticals by 113.4% in the first quarter. Trexquant Investment LP now owns 290,059 shares of the biotechnology company’s stock valued at $1,601,000 after buying an additional 154,105 shares in the last quarter. Finally, PDT Partners LLC raised its position in shares of Enanta Pharmaceuticals by 217.5% in the first quarter. PDT Partners LLC now owns 106,200 shares of the biotechnology company’s stock valued at $586,000 after buying an additional 72,751 shares in the last quarter. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.